These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 16799620)

  • 41. Molecular pathways: the complex roles of inflammation pathways in the development and treatment of liver cancer.
    Nikolaou K; Sarris M; Talianidis I
    Clin Cancer Res; 2013 Jun; 19(11):2810-6. PubMed ID: 23549874
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Growth factor pathways in development and progression of hepatocellular carcinoma.
    Nalesnik MA; Michalopoulos GK
    Front Biosci (Schol Ed); 2012 Jun; 4(4):1487-515. PubMed ID: 22652888
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Growth factors and their receptors.
    Tripathy D; Benz C
    Hematol Oncol Clin North Am; 1994 Feb; 8(1):29-50. PubMed ID: 8150783
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting molecular signal transduction pathways in hepatocellular carcinoma and its implications for cancer therapy.
    Mir IH; Guha S; Behera J; Thirunavukkarasu C
    Cell Biol Int; 2021 Nov; 45(11):2161-2177. PubMed ID: 34270844
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of somatostatin analogs in the management of hepatocellular carcinoma.
    D'Agostino L; Manguso F; Pivonello R; Colao A
    J Endocrinol Invest; 2003; 26(8 Suppl):131-3. PubMed ID: 15233229
    [No Abstract]   [Full Text] [Related]  

  • 46. Liver stem cells and molecular signaling pathways in hepatocellular carcinoma.
    Kitisin K; Pishvaian MJ; Johnson LB; Mishra L
    Gastrointest Cancer Res; 2007; 1(4 Suppl 2):S13-21. PubMed ID: 19360142
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma.
    Geschwind JF; Georgiades CS; Ko YH; Pedersen PL
    Expert Rev Anticancer Ther; 2004 Jun; 4(3):449-57. PubMed ID: 15161443
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Integrin-mediated control of cell growth.
    Schuppan D; Ocker M
    Hepatology; 2003 Aug; 38(2):289-91. PubMed ID: 12883471
    [No Abstract]   [Full Text] [Related]  

  • 49. Growth factors and growth factor receptors.
    Alison MR; Wright NA
    Br J Hosp Med; 1993 Jun 2-15; 49(11):774-5, 778, 781-3 passim. PubMed ID: 8392889
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Role and mechanism of cytokines in the carcinogenesis of liver carcinoma].
    Yao DF
    Zhonghua Gan Zang Bing Za Zhi; 2005 May; 13(5):378-9. PubMed ID: 15918976
    [No Abstract]   [Full Text] [Related]  

  • 51. The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis.
    Berasain C; Avila MA
    J Gastroenterol; 2014 Jan; 49(1):9-23. PubMed ID: 24318021
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Cellular signaling pathways involved in hepatocellular carcinoma occurrence and progression].
    Dai Z; Zhou J; Fan J
    Zhonghua Gan Zang Bing Za Zhi; 2010 Dec; 18(12):955-7. PubMed ID: 21205491
    [No Abstract]   [Full Text] [Related]  

  • 53. Mitochondrial Signaling and Hepatocellular Carcinoma: Molecular Mechanisms and Therapeutic Implications.
    Facciorusso A; Villani R; Bellanti F; Mitarotonda D; Vendemiale G; Serviddio G
    Curr Pharm Des; 2016; 22(18):2689-96. PubMed ID: 26861645
    [TBL] [Abstract][Full Text] [Related]  

  • 54. What is the relationship between epidermal growth factor-like domain 7 and RhoC in metastasis of hepatocellular carcinoma?
    Liu N; Zhang H; Wu K; Fan D
    Hepatology; 2010 Jun; 51(6):2235-6. PubMed ID: 20187105
    [No Abstract]   [Full Text] [Related]  

  • 55. The priming/completion paradigm to explain growth factor-dependent cell cycle progression.
    Kazlauskas A
    Growth Factors; 2005 Sep; 23(3):203-10. PubMed ID: 16243712
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tumor necrosis factor and hypermetabolism.
    Seaton TB; Coombe N; Mittelman A
    Ann Intern Med; 1990 May; 112(9):715-6. PubMed ID: 2159251
    [No Abstract]   [Full Text] [Related]  

  • 57. The Role of Transforming Growth Factor-β in Human Hepatocarcinogenesis: Mechanistic and Therapeutic Implications From an Integrative Multiomics Approach.
    Marquardt JU
    Gastroenterology; 2018 Jan; 154(1):17-20. PubMed ID: 29174548
    [No Abstract]   [Full Text] [Related]  

  • 58. Growth factor-dependent signaling and cell cycle progression.
    Jones SM; Kazlauskas A
    Chem Rev; 2001 Aug; 101(8):2413-23. PubMed ID: 11749380
    [No Abstract]   [Full Text] [Related]  

  • 59. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.
    Giammarile F; Bodei L; Chiesa C; Flux G; Forrer F; Kraeber-Bodere F; Brans B; Lambert B; Konijnenberg M; Borson-Chazot F; Tennvall J; Luster M;
    Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1393-406. PubMed ID: 21494856
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Linking fatty liver diseases to hepatocellular carcinoma by hepatic stellate cells.
    Chen L; Ye X; Yang L; Zhao J; You J; Feng Y
    J Natl Cancer Cent; 2024 Mar; 4(1):25-35. PubMed ID: 39036388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.